Profilo
Mrs. Elise Chemin began her professional career in 2004 in the Equity Capital Markets department of Calyon, then in the European Strategy department of General Motors in Germany.
In 2005, she joined Société Générale in the Leverage Finance team.
She participated in a number of transactions including the buy-outs of RLD or Histoire d’Or, for French as well as international sponsors.
Mrs. Chemin is a graduate of ESCP-EAP, where she majored in Finance.
Precedenti posizioni note di Elise Chemin
| Società | Posizione | Fine |
|---|---|---|
Weinberg Capital Partners SAS
 Weinberg Capital Partners SAS Investment ManagersFinance Weinberg Capital Partners SAS (WCP) is a private equity firm founded in 2005 by Serge Weinberg and Philippe Klocanas. The firm is headquartered in Paris, France. | Analista di Private Equity | 01/04/2012 |
Mutabilis SA
 Mutabilis SA Pharmaceuticals: MajorHealth Technology Mutabilis SA specializes in the discovery and development of anti-infective drugs. It focuses on novel therapeutic approaches for controlling severe and nosocomial infections. The firm offers antibacterial, vaccines, anti-infective agents, gram-positive & negative ant virulence lead series, specific antigens, and screening technologies for antibacterial and virulence targets. The company was founded in 2001 by Xavier Nassif and is headquartered in Romainville, France. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Weinberg Capital Partners SAS
Weinberg Capital Partners SAS Investment ManagersFinance Weinberg Capital Partners SAS (WCP) is a private equity firm founded in 2005 by Serge Weinberg and Philippe Klocanas. The firm is headquartered in Paris, France. | Finance |
Mutabilis SA
Mutabilis SA Pharmaceuticals: MajorHealth Technology Mutabilis SA specializes in the discovery and development of anti-infective drugs. It focuses on novel therapeutic approaches for controlling severe and nosocomial infections. The firm offers antibacterial, vaccines, anti-infective agents, gram-positive & negative ant virulence lead series, specific antigens, and screening technologies for antibacterial and virulence targets. The company was founded in 2001 by Xavier Nassif and is headquartered in Romainville, France. | Health Technology |
- Borsa valori
- Insiders
- Elise Chemin
